The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervicovaginal tissue construct.
Retrocyclins are cyclic antimicrobial peptides that exhibit potent activity towards a broad range of primary and laboratory-adapted strains of human immunodeficiency virus type 1 (HIV-1) in vitro. The current study shows that RC-101, an analogue of retrocyclin, prevented HIV-1 infection in an organ-like construct of human cervicovaginal tissue and retained full activity in the presence of vaginal fluid. The peptide remained within the cervicovaginal tissues throughout the 9-day incubation period without altering tissue viability, inducing damage or inducing the release of inflammatory cytokines. Collectively, these data support the potential development of RC-101 as a topical microbicide to prevent HIV-1 infection and transmission.
Cole
Amy L
AL
Department of Molecular Biology & Microbiology, Biomolecular Science Center, Burnett College of Biomedical Sciences at University of Central Florida, Orlando, FL 32816, USA. acole@mail.ucf.edu
Herasimtschuk
Anna
A
Gupta
Phalguni
P
Waring
Alan J
AJ
Lehrer
Robert I
RI
Cole
Alexander M
AM
D019380:Anti-HIV Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005260:Female; D015658:HIV Infections / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D008954:Models, Biological; D010455:Peptides / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D046509:Tissue Culture Techniques; D014621:Vagina / Q000187:drug effects / Q000821:virology*
D019380:Anti-HIV Agents; D018836:Inflammation Mediators; D010455:Peptides; C450143:RC 101